CEBPA and acute myeloid leukemia: In the European Leukemia Net (ELN) favorable-risk group (patients with CN-AML who have mutated CEBPα and/or mutated NPM1 without FLT3-ITD), TET2-mutated patients had shorter event-free survival (EFS) (p < 0.001), because of a lower complete remission (CR) rate (p = 0.007), shorter disease-free survival (DFS) (p = 0.003) and shorter OS (p = 0.001) compared with TET2-wild-type patients (Table 1).